{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:17:24Z","timestamp":1785295044715,"version":"3.55.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GW4 BioMed MRC DTP","award":["MRC20IIRCa"],"award-info":[{"award-number":["MRC20IIRCa"]}]},{"DOI":"10.13039\/100022942","name":"Moondance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018601","name":"Wales Cancer Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018601","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["DRCRPG-NOV21\/100003"],"award-info":[{"award-number":["DRCRPG-NOV21\/100003"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The landscape of cancer treatment has evolved rapidly within the last 50\u00a0years, and whilst radiotherapy, chemotherapy, and surgery remain the mainstay treatment options, there has been a shift towards using immunotherapy alone or in combination with other treatment modalities. There is an emerging paradigm that radiotherapy is immunogenic, driving stimulation of antigen-specific T cells capable of recognising tumour cells at distal sites to the treatment location.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Whole blood samples were collected from patients with primary and oligometastatic cancer before, during, and after treatment with stereotactic ablative radiotherapy (SABR). Using clinical full blood counts, multiparameter flow cytometry, Luminex, and ELISpot assays, this study explored the impact of SABR on systemic immune cell composition, inflammatory markers, and antigen-specific T cell responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified striking systemic changes collectively indicating profound SABR-driven immunosuppression. Such changes were characterised by pronounced and sustained lymphopenia which included loss of CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, B cells, and natural killer (NK) cells accompanied by an overall decline in effector T cell responses to common recall and cancer antigens. This loss of lymphocytes drove a rise in the neutrophil-to-lymphocyte ratio (NLR), which was associated with poorer progression-free survival (PFS) if increased from baseline. A higher dosage of radiation and treatment to a larger area were both associated with more pronounced lymphocyte loss, a concomitant NLR increase, and poorer PFS, particularly in individuals with liver lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings support a role for lymphocytes in preventing disease progression after SABR and suggest that a change to clinical practice to spare lymphocytes from the toxic effects of irradiation may have beneficial effects for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-025-04218-6","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:14:03Z","timestamp":1766060043000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Jessica","family":"Oliver","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Capitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Poon-King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Milutinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Kuczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rackley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pembroke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Godkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awen M.","family":"Gallimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"issue":"5","key":"4218_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411\u2013422. https:\/\/doi.org\/10.1056\/NEJMoa1001294","journal-title":"N Engl J Med"},{"issue":"17","key":"4218_CR2","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F et al (2022) Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers 14(17):4160. https:\/\/doi.org\/10.3390\/cancers14174160","journal-title":"Cancers"},{"issue":"1","key":"4218_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RHI Andtbacka","year":"2019","unstructured":"Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, \u04e6hrling K et al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7(1):145. https:\/\/doi.org\/10.1186\/s40425-019-0623-z","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4218_CR4","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, O\u2019Day S (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24(10):2694\u20132698. https:\/\/doi.org\/10.1093\/annonc\/mdt291","journal-title":"Ann Oncol"},{"issue":"21","key":"4218_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/nejmoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/nejmoa1501824","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"4218_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP et al (2005) Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11(2 Pt 1):728\u2013734. https:\/\/doi.org\/10.1158\/1078-0432.728.11.2","journal-title":"Clin Cancer Res"},{"issue":"20","key":"4218_CR7","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/nejmoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med 377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/nejmoa1709937","journal-title":"N Engl J Med"},{"key":"4218_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1056\/nejmoa1709937","volume":"174","author":"Y Liu","year":"2022","unstructured":"Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G et al (2022) Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: the phase II DETERRED trial. Lung Cancer 174:112\u2013117. https:\/\/doi.org\/10.1056\/nejmoa1709937","journal-title":"Lung Cancer"},{"issue":"1\u20132","key":"4218_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/critrevoncog.v18.i1-2.40","volume":"18","author":"TN Seyfried","year":"2013","unstructured":"Seyfried TN, Huysentruyt LC (2013) On the origin of cancer metastasis. Crit Rev Oncog 18(1\u20132):43\u201373. https:\/\/doi.org\/10.1615\/critrevoncog.v18.i1-2.40","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"4218_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/jco.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8\u201310. https:\/\/doi.org\/10.1200\/jco.1995.13.1.8","journal-title":"J Clin Oncol"},{"issue":"1133","key":"4218_CR11","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20210033","volume":"95","author":"K Debbi","year":"2022","unstructured":"Debbi K, Loganadane G, To NH, Kinj R, Husain ZA, Chapet S et al (2022) Curative intent stereotactic ablative radiation therapy (SABR) for treatment of lung oligometastases from head and neck squamous cell carcinoma (HNSCC): a multi-institutional retrospective study. Br J Radiol 95(1133):20210033. https:\/\/doi.org\/10.1259\/bjr.20210033","journal-title":"Br J Radiol"},{"issue":"1","key":"4218_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000358750","volume":"9","author":"S Di Lascio","year":"2014","unstructured":"Di Lascio S, Pagani O (2014) Oligometastatic breast cancer: a shift from palliative to potentially curative treatment? Breast Care 9(1):7\u201314. https:\/\/doi.org\/10.1159\/000358750","journal-title":"Breast Care"},{"issue":"5","key":"4218_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101221","volume":"8","author":"HL Cho","year":"2023","unstructured":"Cho HL, Balboni T, Christ SM, Turner B, Spektor A, Perni S (2023) Is oligometastatic cancer curable? A survey of oncologist perspectives, decision making, and communication. Adv Radiat Oncol 8(5):101221. https:\/\/doi.org\/10.1016\/j.adro.2023.101221","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"4218_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/s1470-2045(20)30537-4","volume":"22","author":"A Chalkidou","year":"2021","unstructured":"Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S et al (2021) Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol 22(1):98\u2013106. https:\/\/doi.org\/10.1016\/s1470-2045(20)30537-4","journal-title":"Lancet Oncol"},{"issue":"1","key":"4218_CR15","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2014.11.17","volume":"3","author":"JY Chang","year":"2015","unstructured":"Chang JY (2015) Stereotactic ablative radiotherapy: aim for a cure of cancer. Ann Transl Med 3(1):12. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.11.17","journal-title":"Ann Transl Med"},{"issue":"2","key":"4218_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijrobp.2009.09.042","volume":"76","author":"L Potters","year":"2010","unstructured":"Potters L, Kavanagh B, Galvin JM, Hevezi JM, Janjan NA, Larson DA et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76(2):326\u2013332. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"4218_CR17","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1097\/jto.0b013e31822e71d8","volume":"6","author":"CJ Haasbeek","year":"2011","unstructured":"Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S (2011) Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. J Thorac Oncol 6(12):2036\u20132043. https:\/\/doi.org\/10.1097\/jto.0b013e31822e71d8","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4218_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","volume":"114","author":"S Harrow","year":"2022","unstructured":"Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C et al (2022) Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes. Int J Radiat Oncol Biol Phys 114(4):611\u2013616. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10185","key":"4218_CR19","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393(10185):2051\u20132058. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"issue":"25","key":"4218_CR20","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/jco.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/jco.20.00818","journal-title":"J Clin Oncol"},{"issue":"5","key":"4218_CR21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3390\/cancers14051152","volume":"14","author":"R Kinj","year":"2022","unstructured":"Kinj R, Muggeo E, Schiappacasse L, Bourhis J, Herrera FG (2022) Stereotactic body radiation therapy in patients with oligometastatic disease: clinical state of the art and perspectives. Cancers 14(5):1152. https:\/\/doi.org\/10.3390\/cancers14051152","journal-title":"Cancers"},{"issue":"305","key":"4218_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26(305):234\u2013241. https:\/\/doi.org\/10.1259\/0007-1285-26-305-234","journal-title":"Br J Radiol"},{"key":"4218_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060860","author":"J Boustani","year":"2019","unstructured":"Boustani J, Grapin M, Laurent PA, Apetoh L, Mirjolet C (2019) The 6th r of radiobiology: reactivation of anti-tumor immune response. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11060860","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4218_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J (2018) Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11(1):104. https:\/\/doi.org\/10.1186\/s13045-018-0647-8","journal-title":"J Hematol Oncol"},{"issue":"6","key":"4218_CR25","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1042\/ebc20220248","volume":"67","author":"C Galassi","year":"2023","unstructured":"Galassi C, Klapp V, Formenti SC, Demaria S, Galluzzi L (2023) Immunologically relevant effects of radiation therapy on the tumor microenvironment. Essays Biochem 67(6):979\u2013989. https:\/\/doi.org\/10.1042\/ebc20220248","journal-title":"Essays Biochem"},{"issue":"3","key":"4218_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/erv.10.169","volume":"10","author":"M Slota","year":"2011","unstructured":"Slota M, Lim JB, Dang Y, Disis ML (2011) ELispot for measuring human immune responses to vaccines. Expert Rev Vaccines 10(3):299\u2013306. https:\/\/doi.org\/10.1586\/erv.10.169","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"4218_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/cells1020111","volume":"1","author":"AM Malyguine","year":"2012","unstructured":"Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers TJ (2012) ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials. Cells 1(2):111\u2013126. https:\/\/doi.org\/10.3390\/cells1020111","journal-title":"Cells"},{"issue":"1","key":"4218_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0022-1759(01)00535-x","volume":"260","author":"JR Currier","year":"2002","unstructured":"Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S et al (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1):157\u2013172. https:\/\/doi.org\/10.1016\/s0022-1759(01)00535-x","journal-title":"J Immunol Methods"},{"key":"4218_CR29","doi-asserted-by":"publisher","first-page":"1202157","DOI":"10.3389\/fimmu.2023.1202157","volume":"14","author":"R Pichler","year":"2023","unstructured":"Pichler R, Diem G, Hackl H, Koutn\u00edk J, Mertens LS, Da D et al (2023) Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2. Front Immunol 14:1202157. https:\/\/doi.org\/10.3389\/fimmu.2023.1202157","journal-title":"Front Immunol"},{"issue":"1","key":"4218_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12936-014-0539-5","volume":"14","author":"D Anum","year":"2015","unstructured":"Anum D, Kusi KA, Ganeshan H, Hollingdale MR, Ofori MF, Koram KA et al (2015) Measuring naturally acquired ex vivo IFN-\u03b3 responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults. Malar J 14(1):20. https:\/\/doi.org\/10.1186\/s12936-014-0539-5.","journal-title":"Malar J"},{"issue":"2","key":"4218_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/mi.2013.62","volume":"7","author":"M Scurr","year":"2014","unstructured":"Scurr M, Ladell K, Besneux M, Christian A, Hockey T, Smart K et al (2014) Highly prevalent colorectal cancer-infiltrating LAP\u207a Foxp3\u207b T cells exhibit more potent immunosuppressive activity than Foxp3\u207a regulatory T cells. Mucosal Immunol 7(2):428\u2013439. https:\/\/doi.org\/10.1038\/mi.2013.62","journal-title":"Mucosal Immunol"},{"key":"4218_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010222","author":"B Geboers","year":"2025","unstructured":"Geboers B, Timmer F, Vos D, Scheffer H, Bakker J, Ruarus A et al (2025) Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010222","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4218_CR33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13104-016-2335-5","volume":"10","author":"P Forget","year":"2017","unstructured":"Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M (2017) What is the normal value of the neutrophil-to-lymphocyte ratio? BMC Res Notes 10(1):12. https:\/\/doi.org\/10.1186\/s13104-016-2335-5","journal-title":"BMC Res Notes"},{"issue":"4","key":"4218_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/life12040465","volume":"12","author":"N Simoni","year":"2022","unstructured":"Simoni N, Rossi G, Cellini F, Vitolo V, Orlandi E, Valentini V et al (2022) Ablative radiotherapy (ART) for locally advanced pancreatic cancer (LAPC): Toward a new paradigm? Life 12(4):465. https:\/\/doi.org\/10.3390\/life12040465","journal-title":"Life"},{"issue":"6","key":"4218_CR35","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/ppo.0000000000000292","volume":"23","author":"CH Crane","year":"2017","unstructured":"Crane CH, O\u2019Reilly EM (2017) Ablative radiotherapy doses for locally advanced. Cancer J 23(6):350\u2013354. https:\/\/doi.org\/10.1097\/ppo.0000000000000292","journal-title":"Cancer J"},{"issue":"11","key":"4218_CR36","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00262-014-1593-0","volume":"63","author":"L Chudley","year":"2014","unstructured":"Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM et al (2014) Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother 63(11):1199\u20131211. https:\/\/doi.org\/10.1007\/s00262-014-1593-0","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4218_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2567.2009.03073.x","volume":"128","author":"SM Todryk","year":"2009","unstructured":"Todryk SM, Pathan AA, Keating S, Porter DW, Berthoud T, Thompson F et al (2009) The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 128(1):83\u201391. https:\/\/doi.org\/10.1111\/j.1365-2567.2009.03073.x","journal-title":"Immunology"},{"key":"4218_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13027-015-0039-4","author":"K Schlick","year":"2015","unstructured":"Schlick K, Grundbichler M, Auberger J, Kern JM, Hell M, Hohla F et al (2015) Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. Infect Agent Cancer. https:\/\/doi.org\/10.1186\/s13027-015-0039-4","journal-title":"Infect Agent Cancer"},{"key":"4218_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104103","volume":"81","author":"C S\u00f6derberg-Naucl\u00e9r","year":"2022","unstructured":"S\u00f6derberg-Naucl\u00e9r C (2022) New mechanistic insights of the pathogenicity of high-risk cytomegalovirus (CMV) strains derived from breast cancer: hope for new cancer therapy options. EBioMedicine 81:104103. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104103","journal-title":"EBioMedicine"},{"issue":"13","key":"4218_CR40","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.ccr-19-3195","volume":"26","author":"NL Goerig","year":"2020","unstructured":"Goerig NL, Frey B, Korn K, Fleckenstein B, \u00dcberla K, Schmidt MA et al (2020) Early mortality of brain cancer patients and its connection to cytomegalovirus reactivation during radiochemotherapy. Clin Cancer Res 26(13):3259\u20133270. https:\/\/doi.org\/10.1158\/1078-0432.ccr-19-3195","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4218_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317717718","volume":"39","author":"A Nandakumar","year":"2017","unstructured":"Nandakumar A, Uwatoko F, Yamamoto M, Tomita K, Majima HJ, Akiba S et al (2017) Radiation-induced Epstein-Barr virus reactivation in gastric cancer cells with latent EBV infection. Tumour Biol 39(7):1010428317717718. https:\/\/doi.org\/10.1177\/1010428317717718","journal-title":"Tumour Biol"},{"issue":"9","key":"4218_CR42","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1182\/blood.v82.9.2767.bloodjournal8292767","volume":"82","author":"P Sansoni","year":"1993","unstructured":"Sansoni P, Cossarizza A, Brianti V, Fagnoni F, Snelli G, Monti D et al (1993) Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82(9):2767\u20132773. https:\/\/doi.org\/10.1182\/blood.v82.9.2767.bloodjournal8292767","journal-title":"Blood"},{"issue":"4","key":"4218_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.humimm.2011.01.009","volume":"72","author":"A Almeida-Oliveira","year":"2011","unstructured":"Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro Ados S, Falc\u00e3o RR et al (2011) Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol 72(4):319\u2013329. https:\/\/doi.org\/10.1016\/j.humimm.2011.01.009","journal-title":"Hum Immunol"},{"issue":"3","key":"4218_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/acel.12191","volume":"13","author":"SK Garg","year":"2014","unstructured":"Garg SK, Delaney C, Toubai T, Ghosh A, Reddy P, Banerjee R et al (2014) Aging is associated with increased regulatory T-cell function. Aging Cell 13(3):441\u2013448. https:\/\/doi.org\/10.1111\/acel.12191","journal-title":"Aging Cell"},{"key":"4218_CR45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0035","author":"M Scurr","year":"2013","unstructured":"Scurr M, Bloom A, Pembroke T, Srinivasan R, Brown C, Smart K et al (2013) Escalating regulation of 5T4-specific IFN-\u03b3(+) CD4(+) T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunol Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0035","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"4218_CR46","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1136\/gutjnl-2011-300970","volume":"61","author":"G Betts","year":"2012","unstructured":"Betts G, Jones E, Junaid S, El-Shanawany T, Scurr M, Mizen P et al (2012) Suppression of tumour-specific CD4\u207a T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61(8):1163\u20131171. https:\/\/doi.org\/10.1136\/gutjnl-2011-300970","journal-title":"Gut"},{"issue":"22","key":"4218_CR47","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/1078-0432.ccr-17-0895","volume":"23","author":"M Scurr","year":"2017","unstructured":"Scurr M, Pembroke T, Bloom A, Roberts D, Thomson A, Smart K et al (2017) Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res 23(22):6771\u20136780. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-0895","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4218_CR48","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ijrobp.2024.01.008","volume":"118","author":"S Baker","year":"2024","unstructured":"Baker S, Lechner L, Liu M, Chang JS, Cruz-Lim EM, Mou B et al (2024) Upfront versus delayed systemic therapy in patients with oligometastatic cancer treated with SABR in the phase 2 SABR-5 trial. Int J Radiat Oncol Biol Phys 118(5):1497\u20131506. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4218_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091597","author":"CB Ho","year":"2023","unstructured":"Ho CB, Tsai JT, Chen CY, Shiah HS, Chen HY, Ting LL et al (2023) Effectiveness of stereotactic ablative radiotherapy for systemic therapy respondents with inoperable pulmonary oligometastases and oligoprogression. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics13091597","journal-title":"Diagnostics"},{"issue":"16","key":"4218_CR50","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1002\/cncr.30693","volume":"123","author":"B Sun","year":"2017","unstructured":"Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF et al (2017) 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non\u2013small cell lung cancer: results of a phase 2 clinical trial. Cancer 123(16):3031\u20133039. https:\/\/doi.org\/10.1002\/cncr.30693","journal-title":"Cancer"},{"issue":"20","key":"4218_CR51","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.ccr-17-3427","volume":"24","author":"AE Marciscano","year":"2018","unstructured":"Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ et al (2018) Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res 24(20):5058\u20135071. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3427","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4218_CR52","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1038\/s41467-022-34676-w","volume":"13","author":"LB Darragh","year":"2022","unstructured":"Darragh LB, Gadwa J, Pham TT, Van Court B, Neupert B, Olimpo NA et al (2022) Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors. Nat Commun 13(1):7015. https:\/\/doi.org\/10.1038\/s41467-022-34676-w","journal-title":"Nat Commun"},{"issue":"5","key":"4218_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3892\/mco.2022.2531","volume":"16","author":"Y Yu","year":"2022","unstructured":"Yu Y, Tan D, Liao C, Yang P, Hu Z, Liang H (2022) Neutrophil-to-lymphocyte ratio as a prognostic predictor for patients with cancer treated with stereotactic body radiation therapy: a meta-analysis. Mol Clin Oncol 16(5):98. https:\/\/doi.org\/10.3892\/mco.2022.2531","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"4218_CR54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/jto.0000000000000399","volume":"10","author":"NA Cannon","year":"2015","unstructured":"Cannon NA, Meyer J, Iyengar P, Ahn C, Westover KD, Choy H et al (2015) Neutrophil\u2013lymphocyte and platelet\u2013lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non\u2013small-cell lung cancer. J Thorac Oncol 10(2):280\u2013285. https:\/\/doi.org\/10.1097\/jto.0000000000000399","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4218_CR55","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.jtho.2017.02.018","volume":"12","author":"B Sun","year":"2017","unstructured":"Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M et al (2017) Long-term outcomes of salvage stereotactic ablative radiotherapy for isolated lung recurrence of non-small cell lung cancer: a phase II clinical trial. J Thorac Oncol 12(6):983\u2013992. https:\/\/doi.org\/10.1016\/j.jtho.2017.02.018","journal-title":"J Thorac Oncol"},{"issue":"4","key":"4218_CR56","doi-asserted-by":"publisher","first-page":"245","DOI":"10.20452\/pamw.3997","volume":"127","author":"J Rutkowski","year":"2017","unstructured":"Rutkowski J, \u015alebioda T, Kmie\u0107 Z, Zaucha R (2017) Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer. Pol Arch Intern Med 127(4):245\u2013253. https:\/\/doi.org\/10.20452\/pamw.3997","journal-title":"Pol Arch Intern Med"},{"issue":"8","key":"4218_CR57","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/j.clon.2021.03.019","volume":"33","author":"A Punjabi","year":"2021","unstructured":"Punjabi A, Barrett E, Cheng A, Mulla A, Walls G, Johnston D et al (2021) Neutrophil-lymphocyte ratio and absolute lymphocyte count as prognostic markers in patients treated with curative-intent radiotherapy for non-small cell lung cancer. Clin Oncol 33(8):e331\u2013e338. https:\/\/doi.org\/10.1016\/j.clon.2021.03.019","journal-title":"Clin Oncol"},{"issue":"1","key":"4218_CR58","doi-asserted-by":"publisher","first-page":"11984","DOI":"10.1038\/s41598-024-62662-3","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin X, Chen H, Sun Y, Xiao L, Lu H, Guo W et al (2024) Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy. Sci Rep 14(1):11984. https:\/\/doi.org\/10.1038\/s41598-024-62662-3","journal-title":"Sci Rep"},{"key":"4218_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.01.003","volume":"123","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mallick S, Lin SH, Krishnan S (2018) A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol 123:42\u201351. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.01.003","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"4218_CR60","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s00066-019-01462-5","volume":"195","author":"HK Byun","year":"2019","unstructured":"Byun HK, Kim N, Park S, Seong J (2019) Acute severe lymphopenia by radiotherapy is associated with reduced overall survival in hepatocellular carcinoma. Strahlenther Onkol 195(11):1007\u20131017. https:\/\/doi.org\/10.1007\/s00066-019-01462-5","journal-title":"Strahlenther Onkol"},{"key":"4218_CR61","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3389\/fonc.2019.00896","volume":"9","author":"Y Zhuang","year":"2019","unstructured":"Zhuang Y, Yuan BY, Chen GW, Zhao XM, Hu Y, Zhu WC et al (2019) Association between circulating lymphocyte populations and outcome after stereotactic body radiation therapy in patients with hepatocellular carcinoma. Front Oncol 9:896. https:\/\/doi.org\/10.3389\/fonc.2019.00896","journal-title":"Front Oncol"},{"key":"4218_CR62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.ircmb.2023.03.010","volume":"378","author":"K Passelli","year":"2023","unstructured":"Passelli K, Rep\u00e1raz D, Herrera FG (2023) Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy. Int Rev Cell Mol Biol 378:137\u2013156. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.03.010","journal-title":"Int Rev Cell Mol Bioll"},{"issue":"1160","key":"4218_CR63","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/bjr\/tqae100","volume":"97","author":"K Passelli","year":"2024","unstructured":"Passelli K, Rep\u00e1raz D, Kinj R, Herrera FG (2024) Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy. Br J Radiol 97(1160):1378\u20131390. https:\/\/doi.org\/10.1093\/bjr\/tqae100","journal-title":"Br J Radiol"},{"issue":"2","key":"4218_CR64","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semradonc.2019.12.003","volume":"30","author":"P Lambin","year":"2020","unstructured":"Lambin P, Lieverse RIY, Eckert F, Marcus D, Oberije C, van der Wiel AMA et al (2020) Lymphocyte-sparing radiotherapy: the rationale for protecting lymphocyte-rich organs when combining radiotherapy with immunotherapy. Semin Radiat Oncol 30(2):187\u2013193. https:\/\/doi.org\/10.1016\/j.semradonc.2019.12.003","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"4218_CR65","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.3390\/cancers13246193","volume":"99","author":"JY Jin","year":"2017","unstructured":"Jin JY, Hu C, Xiao Y, Zhang H, Ellsworth S, Schild SE et al (2017) Higher radiation dose to immune system is correlated with poorer survival in patients with stage III non\u2013small cell lung cancer: a secondary study of a phase 3 cooperative group trial (NRG Oncology RTOG 0617). Int J Radiat Oncol Biol Phys 99(2):S151\u2013S152. https:\/\/doi.org\/10.3390\/cancers13246193","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4218_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100852","author":"E Prades-Sagarra","year":"2024","unstructured":"Prades-Sagarra E, Yaromina A, Dubois LJ (2024) Understanding the impact of radiation-induced lymphopenia: preclinical and clinical research perspectives. Clin Transl Radiat Oncol. https:\/\/doi.org\/10.1016\/j.ctro.2024.100852","journal-title":"Clin Transl Radiat Oncol"},{"issue":"11","key":"4218_CR67","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1158\/1078-0432.ccr-23-3632","volume":"30","author":"D Morel","year":"2024","unstructured":"Morel D, Robert C, Paragios N, Gr\u00e9goire V, Deutsch E (2024) Translational frontiers and clinical opportunities of immunologically fitted radiotherapy. Clin Cancer Res 30(11):2317\u20132332. https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-3632","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4218_CR68","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40425-016-0149-6","volume":"4","author":"T Crocenzi","year":"2016","unstructured":"Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C et al (2016) A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer 4(1):45. https:\/\/doi.org\/10.1186\/s40425-016-0149-6","journal-title":"J Immunother Cancer"},{"issue":"3","key":"4218_CR69","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","volume":"94","author":"AT Wild","year":"2016","unstructured":"Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM et al (2016) Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 94(3):571\u2013579. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.026","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"4218_CR70","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4143\/crt.2020.1053","volume":"53","author":"HK Byun","year":"2021","unstructured":"Byun HK, Chung SY, Kim KJ, Seong J (2021) Role of interleukin-7 in the development of and recovery from radiation-induced lymphopenia: a post-hoc analysis of a prospective cohort. Cancer Res Treat 53(4):962\u2013972. https:\/\/doi.org\/10.4143\/crt.2020.1053","journal-title":"Cancer Res Treat"},{"issue":"5","key":"4218_CR71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00262-024-03664-y","volume":"73","author":"J Yu","year":"2024","unstructured":"Yu J, Gadwa J, Ross RB, Knitz M, Darragh LB, Abdelazeem KNM et al (2024) IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models. Cancer Immunol Immunother 73(5):90. https:\/\/doi.org\/10.1007\/s00262-024-03664-y","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4218_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101118","volume":"14","author":"Z Chen","year":"2021","unstructured":"Chen Z, Wu Z, Muluh TA, Fu S, Wu J (2021) Effect of low-dose total-body radiotherapy on immune microenvironment. Transl Oncol 14(8):101118. https:\/\/doi.org\/10.1016\/j.tranon.2021.101118","journal-title":"Transl Oncol"},{"key":"4218_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101710","volume":"35","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang A (2023) Low-dose radiotherapy effects the progression of anti-tumor response. Transl Oncol 35:101710. https:\/\/doi.org\/10.1016\/j.tranon.2023.101710","journal-title":"Transl Oncol"},{"issue":"1","key":"4218_CR74","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.cd-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, Ronet C, Ochoa De Olza M, Barras D, Crespo I, Andreatta M et al (2022) Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy. Cancer Discov 12(1):108\u2013133. https:\/\/doi.org\/10.1158\/2159-8290.cd-21-0003","journal-title":"Cancer Discov"},{"issue":"5","key":"4218_CR75","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00262-018-2141-0","volume":"67","author":"A Domouchtsidou","year":"2018","unstructured":"Domouchtsidou A, Barsegian V, Mueller SP, Best J, Ertle J, Bedreli S et al (2018) Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy. Cancer Immunol Immunother 67(5):843\u2013853. https:\/\/doi.org\/10.1007\/s00262-018-2141-0","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"4218_CR76","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2307\/3577549","volume":"123","author":"N Nakamura","year":"1990","unstructured":"Nakamura N, Kusunoki Y, Akiyama M (1990) Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res 123(2):224\u2013227. https:\/\/doi.org\/10.2307\/3577549","journal-title":"Radiat Res"},{"issue":"2","key":"4218_CR77","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1667\/rr0978.1","volume":"173","author":"Y Qu","year":"2010","unstructured":"Qu Y, Jin S, Zhang A, Zhang B, Shi X, Wang J et al (2010) Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice. Radiat Res 173(2):148\u2013157. https:\/\/doi.org\/10.1667\/rr0978.1","journal-title":"Radiat Res"},{"issue":"7","key":"4218_CR78","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.4049\/jimmunol.169.7.3760","volume":"169","author":"JM Grayson","year":"2002","unstructured":"Grayson JM, Harrington LE, Lanier JG, Wherry EJ, Ahmed R (2002) Differential sensitivity of naive and memory CD8+ T cells to apoptosis in vivo. J Immunol 169(7):3760\u20133770. https:\/\/doi.org\/10.4049\/jimmunol.169.7.3760","journal-title":"J Immunol"},{"issue":"1","key":"4218_CR79","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1038\/s41467-019-11906-2","volume":"10","author":"A Arina","year":"2019","unstructured":"Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ et al (2019) Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun 10(1):3959. https:\/\/doi.org\/10.1038\/s41467-019-11906-2","journal-title":"Nat Commun"},{"issue":"11","key":"4218_CR80","first-page":"3276","volume":"5","author":"S Liu","year":"2015","unstructured":"Liu S, Sun X, Luo J, Zhu H, Yang X, Guo Q et al (2015) Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. Am J Cancer Res 5(11):3276\u20133285","journal-title":"Am J Cancer Res"},{"issue":"5","key":"4218_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100505","volume":"4","author":"T Kuge","year":"2023","unstructured":"Kuge T, Shiroyama T, Tamiya A, Tamiya M, Kanazu M, Kinehara Y et al (2023) Impact of lymphopenia recovery after chemoradiotherapy on durvalumab consolidation therapy in stage III NSCLC. JTO Clin Res Rep 4(5):100505. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100505","journal-title":"JTO Clin Res Rep"},{"key":"4218_CR82","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2024.807","author":"H Kim","year":"2024","unstructured":"Kim H, Chun S-J, Sun S, Cho H, Kim T-J, Lee Y-J, et al. (2024) Low-dose cyclophosphamide enhances the tumoricidal effects of 5-day spacing stereotactic ablative radiotherapy by boosting antitumor immunity. J Korean Cancer Assoc. https:\/\/doi.org\/10.4143\/crt.2024.807","journal-title":"J Korean Cancer Assoc"},{"key":"4218_CR83","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166. https:\/\/doi.org\/10.1016\/j.radonc.2020.04.003","journal-title":"Radiother Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04218-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:14:08Z","timestamp":1766060048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04218-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4218"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04218-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for the SABR_IT study was obtained from the Integrated Research Application System (IRAS) in January 2021 (project ID 280149).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"3"}}